Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 901 - 925 of 14534 in total
Ethambutol is a bacteriostatic agent indicated alongside medications such as isoniazid, rifampin, and pyrazinamide in the treatment of pulmonary tuberculosis. Ethambutol was first described in the literature in 1961. It was developed out of a need for therapies active against isoniazid resistant strains of Mycobacterium tuberculosis. Ethambutol was granted FDA...
Approved
Matched Description: … Ethambutol is a bacteriostatic agent indicated alongside medications such as [isoniazid], [rifampin], and
Matched Categories: … ethambutol and isoniazid ... rifampicin, ethambutol and isoniazid ... rifampicin, pyrazinamide, ethambutol and isoniazid …
Penbutolol is a drug in the beta-blocker class used to treat hypertension. Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker. Penbutolol can act as a partial agonist at beta adrenergic receptors, since it is a sympathomimetric drug. Penbutolol also demonstrates high binding affinity to the...
Approved
Investigational
Matched Description: … Penbutolol binds both beta-1 and beta-2 adrenergic receptors, rendering it a non-selective beta-blocker ... degree atrioventricular conduction block, bronchial asthma, and those with known hypersensitivity. ... Penbutolol is contraindicated in patients with cardiogenic shock, sinus bradycardia, second and third …
Matched Categories: … penbutolol and other diuretics …
Sulfaphenazole is a sulfonamide antibacterial.
Approved
Matched Categories: … Sulfonamides and trimethoprim ... Genito Urinary System and Sex Hormones ... Gynecological Antiinfectives and Antiseptics …
Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune responses. Baricitinib was...
Approved
Investigational
Matched Description: … By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated inflammation and immune ... European Commission (EC) in February 2017 for the treatment of rheumatoid arthritis in adults [A248395] and
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on...
Approved
Investigational
Matched Description: … [A40009] Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Amoxapine, the N-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, amoxapine does not affect mood or arousal, but may cause sedation....
Approved
Matched Description: … , and mixed symptoms of depression and anxiety or agitation. ... Amoxapine may be used to treat neurotic and reactive depressive disorders, endogenous and psychotic depression ... TCAs are potent inhibitors of serotonin and norepinephrine reuptake. …
Ethyl macadamiate is derived from Macadamia terifolia seed oil. It is a non-volatile ester of ethyl alcohol and the fatty acids. Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.
Approved
Matched Description: … and skin care products as an emollient and skin conditioning agent. ... It is a non-volatile ester of ethyl alcohol and the fatty acids. ... Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products …
Pegaptanib is a polynucleotide aptamer. Pegatinib aids neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and vessel permeability. Pegaptanib was granted FDA approval on 17 September 2004.
Approved
Investigational
Matched Description: … neovascular age-related macular degeneration by binding to VEGF which in order reduces angiogenesis and
Matched Categories: … Nucleic Acids, Nucleotides, and Nucleosides …
Approved
Experimental
Investigational
Matched Categories: … Alimentary Tract and Metabolism …
The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. It tends to cause less severe disease but is significantly more virulent than both the original virus and earlier variants (e.g. Delta). As of November 2022, it is the primary circulating variant of...
Approved
Investigational
Matched Description: … [L43922] The Omicron variant comprises several distinct lineages and sublineages (e.g. ... tends to cause less severe disease but is significantly more virulent than both the original virus and ... Famtozinameran is an mRNA vaccine encoding the S glycoprotein of SARS-CoV-2 Omicron variant lineages BA.4 and
Matched Categories: … Amino Acids, Peptides, and Proteins …
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
Approved
Investigational
Withdrawn
Matched Description: … Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections …
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is...
Approved
Matched Description: … receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and ... amongst overactive bladder treatment options in that, unlike other treatments such as [solifenacin] and ... a comparatively favorable adverse effect profile as compared to other available treatment options, and
Matched Categories: … Genito Urinary System and Sex Hormones ... Drugs for Urinary Frequency and Incontinence …
Viloxazine is a selective norepinephrine reuptake inhibitor. For decades, an immediate-release formulation of viloxazine has been used in Europe as an antidepressant. It was first approved in the UK in 1974; however, the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and efficacy. In the US,...
Approved
Investigational
Withdrawn
Matched Description: … the immediate-release formulation was discontinued due to business reasons unrelated to drug safety and ... designation in 1984 under the brand name CATATROL: while this product was intended to treat cataplexy and
Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. A common pharmaceutical formulation of thonzonium bromide is...
Approved
Matched Description: … It is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular ... Thonzonium is a monocationic surface-active agent with surfactant and detergent properties. ... debris and exudate, thereby promoting tissue contact of the administered medication. …
Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac. Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders of Gallbladder, Biliary Tract and Pancrease.
Approved
Investigational
Matched Description: … of Gallbladder, Biliary Tract and Pancrease. ... Benzodiazepine is under investigation for the prevention of Delirium and C.Surgical Procedure; Cardiac ... Benzodiazepine has been investigated for the treatment of Obesity, Sleep Apnea, Obstructive, and Disorders …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. It is formulated as a once-daily transdermal patch which provides a slow and constant supply of the drug over the course of 24 hours....
Approved
Matched Description: … restless legs syndrome (RLS) in Europe and the United States. ... It was approved by the European Medicines Agency in 2006 and by the FDA in 2007. ... (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and
Pralsetinib, similar to the previously approved selpercatinib, is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small cell lung cancer. Although multikinase inhibitors, including cabozantinib, ponatinib,...
Approved
Investigational
Matched Description: … Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and ... [A202055] Pralsetinib (BLU-667) and [selpercatinib] (LOXO-292) represent the first generation of specific …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation....
Approved
Investigational
Matched Description: … In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. ... agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and ... These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation...
Approved
Investigational
Matched Description: … [L6676] Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. ... [A179398] It is most commonly marketed under the name Inlyta® and is available in oral formulations. …
Matched Categories: … Benzamides and benzamide derivatives ... Antineoplastic and Immunomodulating Agents …
Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder. It is a piperazinyl-triazole derivative.
Approved
Matched Description: … Lorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive …
Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia. IV administration of propfol is used to induce unconsciousness after which anaesthesia may be maintained using a combination of medications. Recovery from propofol-induced anaesthesia is generally rapid and associated with less frequent side effects (e.g. drowsiness,...
Approved
Investigational
Vet approved
Matched Description: … for induction and/or maintenance of anaesthesia prior to and during surgeries. ... Propofol is an intravenous anaesthetic agent used for induction and maintenance of general anaesthesia ... effects (e.g. drowsiness, nausea, vomiting) than with thiopental, methohexital, and etomidate. …
Matched Categories: … Hypnotics and Sedatives …
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of inflammatory mediators like tumor necrosis factor-alpha...
Approved
Investigational
Withdrawn
Matched Description: … It has been reintroduced and used for a number of inflammatory disorders and cancers. ... inflammatory mediators like tumor necrosis factor-alpha (TNF-a) and other cytokine action. ... Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating the release of …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Oteracil is an adjunct to antineoplastic therapy, used to reduce the toxic side effects associated with chemotherapy. Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with DB09257 and DB09256 within the commercially available product "Teysuno". The main active ingredient in Teysuno is DB09256,...
Approved
Matched Description: … European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and ... By mimicking a class of compounds called "pyrimidines" that are essential components of RNA and DNA, ... 5-FU is able to insert itself into strands of DNA and RNA, thereby halting the replication process necessary …
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab...
Approved
Matched Description: … (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils ... signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and ... type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis treatment options, nintedanib is currently one...
Approved
Matched Description: … used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and ... agent for NSCLC, nintedanib, in combination with [Docetaxel], is reserved for patients who have tried and ... indicated for the condition (the other being [Pirfenidone]) and as such is used as a first-line treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Displaying drugs 901 - 925 of 14534 in total